Shares of Insulet Corporation (NASDAQ:PODD – Get Free Report) have been given a consensus rating of “Moderate Buy” by the twenty-eight ratings firms that are covering the stock, MarketBeat.com reports. Two analysts have rated the stock with a sell rating, four have assigned a hold rating and twenty-two have assigned a buy rating to the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $235.25.
A number of analysts have issued reports on PODD shares. TD Cowen lowered their target price on Insulet from $379.00 to $294.00 and set a “hold” rating on the stock in a report on Monday, June 1st. Wells Fargo & Company cut their price target on Insulet from $360.00 to $255.00 and set an “overweight” rating for the company in a report on Wednesday, May 6th. Wall Street Zen cut Insulet from a “strong-buy” rating to a “buy” rating in a research report on Saturday, June 27th. Raymond James Financial set a $216.00 price objective on shares of Insulet in a research note on Monday, June 8th. Finally, Piper Sandler dropped their target price on shares of Insulet from $360.00 to $210.00 in a research report on Wednesday, May 6th.
Read Our Latest Stock Analysis on Insulet
Insulet News Roundup
- Negative Sentiment: Multiple law firms announced or promoted class action lawsuits against Insulet, with investors urged to contact counsel ahead of the August 31 lead-plaintiff deadline. These actions add legal overhang and keep attention on prior disclosures.PODD Investors Have Opportunity to Lead Insulet Corporation Securities Fraud Lawsuit
- Negative Sentiment: The lawsuits allege Insulet misled investors about manufacturing controls at its Acton facility, including claims that defective controls may have produced millions of flawed Omnipod pods and created insulin under-delivery risks.PODD Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Insulet Corporation Securities Lawsuit – Contact Levi & Korsinsky
- Neutral Sentiment: The company’s last reported earnings were strong, with revenue and EPS beating Wall Street expectations and year-over-year revenue growth of 33.9%, which helps offset some of the legal concerns but is not the main driver of today’s move.
Insulet Stock Down 0.3%
Insulet stock opened at $158.38 on Friday. The company has a debt-to-equity ratio of 0.71, a current ratio of 2.49 and a quick ratio of 1.81. Insulet has a fifty-two week low of $138.79 and a fifty-two week high of $354.88. The firm has a fifty day moving average price of $153.77 and a two-hundred day moving average price of $202.89. The firm has a market cap of $10.97 billion, a price-to-earnings ratio of 36.83, a P/E/G ratio of 1.11 and a beta of 1.11.
Insulet (NASDAQ:PODD – Get Free Report) last issued its quarterly earnings results on Wednesday, May 6th. The medical instruments supplier reported $1.42 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.19 by $0.23. The company had revenue of $761.70 million for the quarter, compared to the consensus estimate of $729.89 million. Insulet had a return on equity of 26.87% and a net margin of 10.44%.The firm’s revenue was up 33.9% compared to the same quarter last year. During the same period last year, the business posted $1.02 earnings per share. Insulet has set its FY 2026 guidance at 6.210- EPS. As a group, analysts forecast that Insulet will post 6.45 earnings per share for the current year.
Insider Transactions at Insulet
In related news, Director Timothy C. Stonesifer acquired 2,790 shares of the company’s stock in a transaction dated Wednesday, June 3rd. The shares were bought at an average price of $143.51 per share, for a total transaction of $400,392.90. Following the acquisition, the director owned 9,041 shares in the company, valued at $1,297,473.91. This trade represents a 44.63% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.36% of the stock is owned by corporate insiders.
Institutional Investors Weigh In On Insulet
Several hedge funds have recently made changes to their positions in the stock. Larson Financial Group LLC increased its stake in Insulet by 114.6% during the fourth quarter. Larson Financial Group LLC now owns 88 shares of the medical instruments supplier’s stock valued at $25,000 after acquiring an additional 47 shares during the period. University of Texas Texas AM Investment Management Co. bought a new stake in shares of Insulet in the 4th quarter worth approximately $26,000. DV Equities LLC bought a new stake in shares of Insulet in the 4th quarter worth approximately $28,000. Elyxium Wealth LLC acquired a new stake in shares of Insulet during the 4th quarter worth approximately $28,000. Finally, Mcguire Capital Advisors Inc. acquired a new stake in shares of Insulet during the 4th quarter worth approximately $29,000.
About Insulet
Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.
The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.
Featured Stories
- Five stocks we like better than Insulet
- Premium Retail’s Stress Test Is Separating Winners From Losers
- D-Wave Quantum or a Quantum ETF: Which Is the Better Bet?
- GE Vernova Just Sent a Mixed AI Signal to Investors
- Alphabet Crushed Earnings, But One Number Spooked the Market
Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.
